Haemonetics Co. (NYSE:HAE) CFO William P. Mr. Burke sold 13,056 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $114.33, for a total value of $1,492,692.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

William P. Mr. Burke also recently made the following trade(s):

  • On Thursday, October 25th, William P. Mr. Burke sold 841 shares of Haemonetics stock. The shares were sold at an average price of $46.76, for a total value of $39,325.16.

NYSE:HAE traded down $3.47 during trading hours on Friday, hitting $111.61. 667,800 shares of the company’s stock traded hands, compared to its average volume of 461,515. The firm has a market capitalization of $5.95 billion, a price-to-earnings ratio of 59.68, a PEG ratio of 3.67 and a beta of 1.09. Haemonetics Co. has a twelve month low of $53.74 and a twelve month high of $117.56. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.02. The firm had revenue of $241.58 million for the quarter, compared to analyst estimates of $233.44 million. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. Haemonetics’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 earnings per share. Equities analysts forecast that Haemonetics Co. will post 2.33 earnings per share for the current year.

Several equities research analysts have recently commented on the company. Zacks Investment Research raised Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price for the company in a report on Friday, October 12th. Barrington Research reaffirmed a “buy” rating and set a $127.00 target price on shares of Haemonetics in a report on Friday, October 5th. TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Morgan Stanley upped their target price on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, August 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 7th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $113.20.

A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in Haemonetics by 49.3% during the second quarter. Renaissance Technologies LLC now owns 1,969,700 shares of the medical instruments supplier’s stock valued at $176,643,000 after buying an additional 650,200 shares during the period. Jackson Square Partners LLC raised its position in Haemonetics by 15.6% during the third quarter. Jackson Square Partners LLC now owns 1,439,167 shares of the medical instruments supplier’s stock valued at $164,899,000 after buying an additional 194,045 shares during the period. American Century Companies Inc. raised its position in Haemonetics by 231.1% during the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock valued at $115,243,000 after buying an additional 701,976 shares during the period. Acadian Asset Management LLC raised its position in Haemonetics by 28.3% during the second quarter. Acadian Asset Management LLC now owns 888,097 shares of the medical instruments supplier’s stock valued at $79,646,000 after buying an additional 196,154 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Haemonetics by 8.8% during the third quarter. Bank of New York Mellon Corp now owns 854,775 shares of the medical instruments supplier’s stock valued at $97,942,000 after buying an additional 69,094 shares during the period. 96.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/11/10/haemonetics-co-hae-cfo-william-p-mr-burke-sells-13056-shares.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Find a Trading Strategy That Works

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.